Instil Bio
Biotechnology · 14 employees
Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil’s lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers.
Funding history
- Venture - Series Unknown — $185.4M — Feb 2021
- Venture - Series Unknown — $170.2M — Aug 2020
- Seed — $516K — Aug 2020
- Venture - Series Unknown — $25.0M — Aug 2020
- Venture - Series Unknown — $15.0M — Sep 2019
Recent signals
- Jan 06, 2026: Instil Bio Terminates License and Collaboration Agreement with ImmuneOnco
- Jun 02, 2025: Instil Bio Appoints Jamie Freedman as Chief Medical Officer
- Feb 23, 2021: Raised $185.4M in Venture - Series Unknown
- Aug 05, 2020: Raised $170.2M in Venture - Series Unknown
- Aug 05, 2020: Raised $516K in Seed
- Aug 05, 2020: Raised $25.0M in Venture - Series Unknown
- Sep 30, 2019: Raised $15.0M in Venture - Series Unknown
See plans & pricing → Track Instil Bio’s funding, hiring, and signals — with verified contacts — on Fundz.